HILLSBOROUGH, N.C., Oct. 8, 2024 /PRNewswire/ — Adam & Eve and adameve.com, America’s most trusted source for adult products, are never shy when it coming to sharing results from their all-new annual sex survey. This month, the sex-positive company asked over 1000 adults how solo orgasms compare to those with a partner, and the results may surprise you.
While a whopping 65% of the respondents (72% of the males and 57% of the females) said an orgasm was better with a partner, 27% (25% of the males and 29% of the females) said they prefer to climax alone. An additional 9% (7% of the men and 12% of the women) said it was the same either way.
“All orgasms are not created equal,” says Dr. Jenni Skyler, PhD, LMFT, C-PST, and resident sexologist at Adam & Eve. “For women, especially, an orgasm with a partner can take time, patience and a lot of trial and error. It can take a while for couples to get into sync where orgasms are concerned. It also helps to know what works for you via your solo experiences and self-discovery, and to communicate that with a partner.”
Dr. Jennis continues, “Orgasms alone can be amazing… a celebration of one’s self and true self care, while the intimacy and connection through partnered sex can add depth and new sensations as well.”
“Adam & Eve encourages adults to celebrate their sexuality within their own comfort levels. We are happy to provide a variety of toys, lubricants and warming lotions to enhance both partnered and solo sessions,” says Chad Davis, Director of Marketing for Adam & Eve.
The web-based survey, conducted by an independent third party survey company, of over 1,000 American adults age 18 and up, was sponsored by Adam & Eve to study sexual preferences and practices.
For more information about Adam & Eve, visit their website, https://www.adameve.com. For additional information on Adam & Eve, please contact Adam & Eve Director of Public Relations Katy Zvolerin at 919.644.8100 x 3121 or katy@adameve.com.
SOURCE AdamEve.com
New multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance…
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…